Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $3.03 USD
Change Today +0.06 / 2.02%
Volume 13.4K
As of 5:20 PM 07/2/15 All times are local (Market data is delayed by at least 15 minutes).

wafergen bio-systems inc (WGBS) Key Developments

WaferGen Bio-Systems, Inc. Announces Management Changes

WaferGen Bio-systems, Inc. announced that the company has appointed Rolland D. Carlson, President & CEO, effective immediately. Dr. Carlson assumes this role from Ivan Trifunovich who has served as President & CEO of WaferGen since March 2012. Dr. Trifunovich has been appointed Executive Chairman of WaferGen. Most recently, Dr. Carlson served as President & CEO of Asuragen, Inc.

WaferGen Bio-systems, Inc. Reports Unaudited Consolidated Earnings Results for the First Quarter Ended March 31, 2015; Reaffirms Earnings Guidance for the Full Year 2015

WaferGen Bio-systems, Inc. reported unaudited consolidated earnings results for the first quarter ended March 31, 2015. For the quarter, the company's product revenue decreased by $260,000, or 20%, as compared to the three months ended March 31, 2014. Total revenue, including license and royalty revenue was $1,146,000, an 18% decrease from $1,406,000 for the three months ended March 31, 2014. The decrease is primarily due to a reduction in sales of SmartChip capital equipment in the three months ended March 31, 2015, with revenue of $102,000, down 83% from the 2014 period, with certain potential customers unable to get their capital expenditure budgets released. Net loss attributable to stockholders was $4.8 million, or $0.85 per basic and diluted share, compared to a net loss of $2.5 million, or $2.79 per basic and diluted share in the first quarter of 2014. Operating loss was $4,574,000 against $2,653,000 a year ago. Net loss before provision for income taxes was $4,804,000 against $2,543,000 a year ago. The company continues to expect full-year 2015 revenue of $8.0 to $8.5 million, which excludes revenue from company's single cell products, presently being developed.

WaferGen Bio-systems, Inc. to Report Q1, 2015 Results on May 11, 2015

WaferGen Bio-systems, Inc. announced that they will report Q1, 2015 results After-Market on May 11, 2015

WaferGen Bio-systems, Inc., Q1 2015 Earnings Call, May 11, 2015

WaferGen Bio-systems, Inc., Q1 2015 Earnings Call, May 11, 2015

WaferGen Bio-systems, Inc. Announces Research Collaboration with Genentech Initiating its Early Access Program for Single Cell Genomics Technology

WaferGen Bio-systems, Inc. announced that the Company has signed a research collaboration with Genentech to evaluate and apply WaferGen's SmartChipTM platform in single cell sequencing. The joint work is aimed at validating the utility of the SmartChipTM technology for isolating single cells from various tissues and preparing libraries for Next-Generation Sequencing (NGS). Â Genentech represents WaferGen's initial partner in WaferGen's single cell genomics technology-focused Early Access Program. WaferGen successfully completed separate proof-of-concept studies related to isolating single cells with the SmartChipTM earlier this year with both the Broad Institute and BGI. At the throughput level scalable to several thousand cells per sample, the cell's genetic composition was successfully analyzed via the NGS method, thereby demonstrating increased discovery potential in a single workflow. WaferGen continues to believe that the SmartChipTM technology will be able to yield a 50-fold increase in the production of single cells per chip versus current technologies at a fraction of the per cell cost.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
WGBS:US $3.03 USD +0.06

WGBS Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Enzo Biochem Inc $2.91 USD -0.04
Exiqon A/S kr14.60 DKK -0.30
HTG Molecular Diagnostics Inc $12.44 USD +0.45
NanoString Technologies Inc $15.06 USD -0.21
Pacific Biosciences of California Inc $5.20 USD -0.21
View Industry Companies

Industry Analysis


Industry Average

Valuation WGBS Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 3.1x
Price/Book 1.9x
Price/Cash Flow NM Not Meaningful
TEV/Sales 0.7x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact WAFERGEN BIO-SYSTEMS INC, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at